Who to call at Novo Nordisk, and when
Fundz watches for the moments Novo Nordisk starts buying, and tells you who to reach.
- An alert the day Novo Nordisk raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Novo Nordisk, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Novo Nordisk. With Fundz connected, it knows.
Contract Type
partnership
Description
Novo Nordisk and Ascendis have entered into a partnership to develop and commercialize a once-monthly GLP-1 drug, with an initial upfront payment of $285 million. This partnership aims to leverage Novo Nordisk's expertise in diabetes care and Ascendis's innovative therapies for rare diseases.
Quick answer
Novo Nordisk and Ascendis form $285m partnership for once-monthly GLP-1 drug (November 7, 2024). Novo Nordisk is based in Denmark.
- What agreement did Novo Nordisk announce on November 7, 2024?
- Novo Nordisk and Ascendis have entered into a partnership to develop and commercialize a once-monthly GLP-1 drug, with an initial upfront payment of $285 million. This partnership aims to leverage Novo Nordisk's expertise in diabetes care and Ascendis's innovative therapies for rare diseases.
- What does Novo Nordisk do?
- Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark.
- Where is Novo Nordisk based?
- Novo Nordisk is based in Denmark.
Source: Fundz verified event record.
Related People
Agreement Insights
What this usually meansNovo Nordisk signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.